171 related articles for article (PubMed ID: 33747946)
1. Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study.
Del Fiore P; Rastrelli M; Dall'Olmo L; Cavallin F; Cappellesso R; Vecchiato A; Buja A; Spina R; Parisi A; Mazzarotto R; Ferrazzi B; Grego A; Rotondi A; Benna C; Tropea S; Russano F; Filoni A; Bassetto F; Tos APD; Alaibac M; Rossi CR; Pigozzo J; Sileni VC; Mocellin S
Front Oncol; 2021; 11():627527. PubMed ID: 33747946
[TBL] [Abstract][Full Text] [Related]
2. Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site.
Prens SP; van der Ploeg AP; van Akkooi AC; van Montfort CA; van Geel AN; de Wilt JH; Eggermont AM; Verhoef C
Ann Surg Oncol; 2011 Dec; 18(13):3586-92. PubMed ID: 21611857
[TBL] [Abstract][Full Text] [Related]
3. Melanoma of unknown primary origin: a population-based study in the Netherlands.
de Waal AC; Aben KK; van Rossum MM; Kiemeney LA
Eur J Cancer; 2013 Feb; 49(3):676-83. PubMed ID: 23031553
[TBL] [Abstract][Full Text] [Related]
4. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma.
Lee CC; Faries MB; Wanek LA; Morton DL
J Clin Oncol; 2008 Feb; 26(4):535-41. PubMed ID: 18235114
[TBL] [Abstract][Full Text] [Related]
5. Improved survival for stage IV melanoma from an unknown primary site.
Lee CC; Faries MB; Wanek LA; Morton DL
J Clin Oncol; 2009 Jul; 27(21):3489-95. PubMed ID: 19451446
[TBL] [Abstract][Full Text] [Related]
6. Survival after lymphadenectomy of nodal metastases from melanoma of unknown primary site.
Gullestad HP; Ryder T; Goscinski M
J Plast Surg Hand Surg; 2023; 57(1-6):109-114. PubMed ID: 34878354
[TBL] [Abstract][Full Text] [Related]
7. Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis.
Ludwig SV; F Cheng P; Mangana J; Braun R; Dummer R; Koelblinger P
Eur J Dermatol; 2020 Dec; 30(6):699-709. PubMed ID: 33459260
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy.
Verver D; Grünhagen DJ; van Akkooi ACJ; Aarts MJB; van den Berkmortel FWPJ; van den Eertwegh AJM; de Groot JWB; Boers-Sonderen MJ; Haanen JBAG; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Tije AJT; Vreugdenhil G; Verhoef C; van der Veldt AAM
Cancer Immunol Immunother; 2021 Nov; 70(11):3123-3135. PubMed ID: 33774697
[TBL] [Abstract][Full Text] [Related]
9. Patients undergoing lymphadenectomy for stage III melanomas of known or unknown primary site do not differ in outcome.
Hughes MC; Wright A; Barbour A; Thomas J; Smithers BM; Green AC; Khosrotehrani K
Int J Cancer; 2013 Dec; 133(12):3000-7. PubMed ID: 23754707
[TBL] [Abstract][Full Text] [Related]
10. Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease.
van der Ploeg AP; Haydu LE; Spillane AJ; Scolyer RA; Quinn MJ; Saw RP; Shannon KF; Stretch JR; Thompson JF
Ann Surg Oncol; 2014 Sep; 21(9):3108-16. PubMed ID: 24802907
[TBL] [Abstract][Full Text] [Related]
11. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
12. Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population-based study.
Verver D; van der Veldt A; van Akkooi A; Verhoef C; Grünhagen DJ; Louwman WJ
Int J Cancer; 2020 Jan; 146(1):26-34. PubMed ID: 30801710
[TBL] [Abstract][Full Text] [Related]
13. Metastatic melanoma to lymph nodes in patients with unknown primary sites.
Cormier JN; Xing Y; Feng L; Huang X; Davidson L; Gershenwald JE; Lee JE; Mansfield PF; Ross MI
Cancer; 2006 May; 106(9):2012-20. PubMed ID: 16568458
[TBL] [Abstract][Full Text] [Related]
14. The impact of primary melanoma thickness and microscopic tumor burden in sentinel lymph nodes on melanoma patient survival.
Baehner FL; Li R; Jenkins T; Hwang J; Kashani-Sabet M; Allen RE; Leong SP
Ann Surg Oncol; 2012 Mar; 19(3):1034-42. PubMed ID: 21989664
[TBL] [Abstract][Full Text] [Related]
15. Melanoma without a detectable primary site with metastases to lymph nodes.
Rutkowski P; Nowecki ZI; Dziewirski W; Zdzienicki M; Pieñkowski A; Salamacha M; Michej W; Trepka S; Bylina E; Ruka W
Dermatol Surg; 2010 Jun; 36(6):868-76. PubMed ID: 20482725
[TBL] [Abstract][Full Text] [Related]
16. Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009.
Pfeil AF; Leiter U; Buettner PG; Eigentler TK; Weide B; Meier F; Garbe C
Melanoma Res; 2011 Jun; 21(3):228-34. PubMed ID: 21502902
[TBL] [Abstract][Full Text] [Related]
17. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.
Morton DL; Hsueh EC; Essner R; Foshag LJ; O'Day SJ; Bilchik A; Gupta RK; Hoon DS; Ravindranath M; Nizze JA; Gammon G; Wanek LA; Wang HJ; Elashoff RM
Ann Surg; 2002 Oct; 236(4):438-48; discussion 448-9. PubMed ID: 12368672
[TBL] [Abstract][Full Text] [Related]
18. Stage IV melanoma of unknown primary: A population-based study in the United States from 1973 to 2014.
Scott JF; Conic RZ; Thompson CL; Gerstenblith MR; Bordeaux JS
J Am Acad Dermatol; 2018 Aug; 79(2):258-265.e4. PubMed ID: 29580859
[TBL] [Abstract][Full Text] [Related]
19. Multidisciplinary Care for Melanoma of Unknown Primary: Experience in the Era of Molecular Profiling.
De Andrade JP; Wong P; O'Leary MP; Parekh V; Amini A; Schoellhammer HF; Margolin KA; Afkhami M; Melstrom LG
Ann Surg Oncol; 2020 Dec; 27(13):5240-5247. PubMed ID: 32909128
[TBL] [Abstract][Full Text] [Related]
20. Melanoma of unknown primary: New perspectives for an old story.
Boussios S; Rassy E; Samartzis E; Moschetta M; Sheriff M; Pérez-Fidalgo JA; Pavlidis N
Crit Rev Oncol Hematol; 2021 Feb; 158():103208. PubMed ID: 33383207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
